Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma
Clinical trial NCT03173560 · COMPLETED
Trial details
- NCT number
- NCT03173560
- Sponsor
- Eisai Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-08-17
- Primary completion
- 2020-02-14
- Enrollment
- 343
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.